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SUMMARY
In May 2001, the World Health Assembly (WHA) passed a resolution which urged member states to attain, by 2010,
aminimum target of regularly administering anthelminthic drugs to at least 75% and up to 100% of all school-aged children
at risk of morbidity. The reﬁned global strategy for the prevention and control of schistosomiasis and soil-transmitted
helminthiasis was issued in the following year and large-scale administration of anthelminthic drugs endorsed as the central
feature. This strategy has subsequently been termed ‘preventive chemotherapy’. Clearly, the 2001WHA resolution led the
way for concurrently controlling multiple neglected tropical diseases. In this paper, we recall the schistosomiasis situation
in Africa inmid-2003. Adhering to strategic guidelines issued by theWorldHealth Organization, we estimate the projected
annual treatment needs with praziquantel among the school-aged population and critically discuss these estimates. The
important role of geospatial tools for disease risk mapping, surveillance and predictions for resource allocation is em-
phasised.We clarify that schistosomiasis is only one of many neglected tropical diseases and that considerable uncertainties
remain regarding global burden estimates. We examine new control initiatives targeting schistosomiasis and other tropical
diseases that are often neglected. The prospect and challenges of integrated control are discussed and the need for com-
bining biomedical, educational and engineering strategies and geospatial tools for sustainable disease control are high-
lighted. We conclude that, for achieving integrated and sustainable control of neglected tropical diseases, a set of
interventions must be tailored to a given endemic setting and ﬁne-tuned over time in response to the changing nature and
impact of control. Consequently, besides the environment, the prevailing demographic, health and social systems contexts
need to be considered.
Key words: Schistosomiasis, soil-transmitted helminthiasis, neglected tropical diseases, epidemiology, control, burden,
morbidity, praziquantel, chemotherapy, integration, health systems, sustainability, Africa.
INTRODUCTION
Schistosomiasis has been known since antiquity
(Adamson, 1976; Davis, 2009) and, from a global
public health perspective, is the most important
water-based disease (Steinmann et al. 2006). On the
one hand, schistosomiasis has been eliminated from
Japan and Tunisia, and is close to elimination
in Morocco and some Caribbean islands (Tanaka
and Tsuji, 1997; Hillyer et al. 1999; Jordan, 2000;
Laamrani et al. 2000). Moreover, substantial prog-
ress has been made in the control of this disease in
Brazil, China andEgypt (Engels et al. 2002;Utzinger
et al. 2005; Stothard et al. 2009). On the other
hand, schistosomiasis has spread to previously non-
endemic areas and there are growing concerns that
water-resource development projects such as large
dams and irrigation systems (Lerer and Scudder,
1999; Fenwick, 2006; Steinmann et al. 2006; Li
et al. 2007) and global warming (Martens, Jetten and
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Focks, 1997; Yang et al. 2005; Zhou et al.
2008) might further exacerbate schistosomiasis
transmission. Schistosomiasis is still concentrated
in sub-Saharan Africa where the bulk of the at-risk
population, existing schistosome infections, mor-
tality, morbidity and burden due to the disease re-
sides (WHO, 2002; Gryseels et al. 2006; Steinmann
et al. 2006).
Despite the public health importance of schisto-
somiasis and the risk that the disease might further
spread and intensify in the absence of comprehensive
mitigation measures, schistosomiasis has been neg-
lected for decades, due to many interrelated factors.
Firstly, the occurrence of schistosomiasis is conﬁned
to the tropics and subtropics, primarily aﬀecting the
poor segments of a population and the distribution
of the disease is focal (Lengeler, Utzinger and
Tanner, 2002; Hotez and Fenwick, 2009). Poor rural
and urban communities are usually underserved and
marginalized, and their voices not heard suﬃciently
to establish this disease ﬁrmly within a national
political agenda (Hotez et al. 2008). Moreover,
national health budgets are chronically under-
funded and governments have to target interventions
and prioritize among many competing interests
(Baltussen, 2006). Secondly, schistosomiasis is a
chronic and debilitating disease, causing mainly
subtle morbidities. Hence, schistosomiasis features
much less prominently on national strategic plans
and on global health initiatives, which still tend to
focus on mortality outcomes and consequently focus
onmalaria, tuberculosis andHIV/AIDS (Hotez et al.
2006; King and Bertino, 2008). This is despite the
paradigm shift introduced with the World Devel-
opment Report 1993, when one started to consider
reducing overall burden of diseases instead of max-
imizing good health as a basis for priority setting and
resources allocation (World Bank, 1993). Thirdly
and connected to this paradigm shift, the global
burden of schistosomiasis, as expressed in disability-
adjusted life years (DALYs) lost, has been seriously
underestimated for schistosomiasis. Hence, insuf-
ﬁcient resources have been allocated for research
and control (King, Dickman and Tisch, 2005;
Bergquist, Utzinger and McManus, 2008; King and
Dangerﬁeld-Cha, 2008; Hotez and Fenwick, 2009).
In this paper we focus on Africa and ﬁrst recall the
schistosomiasis situation inmid-2003, just before the
launch of a new wave of large-scale control in-
itiatives. On the basis of schistosomiasis endemicity
and recommended treatment strategies put forward
by the World Health Organization (WHO), we esti-
mate annual treatment needs with praziquantel
among the school-aged population. We then review
the collective burden of the neglected tropical dis-
eases, including current uncertainties, and welcome
new research that will re-estimate the global burden
of more than 150 diseases and risk factors, including
schistosomiasis. Next, we discuss the concept of
integrated control of neglected tropical diseases and
compare vertical mass campaigns withmore systemic
approaches. The scope and limits of contemporary
initiatives to control schistosomiasis and other neg-
lected tropical diseases are examined. We conclude
that for achieving integration and sustainability of
neglected tropical disease control, a package of in-
terventions is required that is readily tailored to a
given endemic setting and is ﬁne-tuned over time.
Interventions therefore must not only consider the
environment inclusive of the intermediate host snails
of schistosomes and the potential of new geospatial
tools and preventive engineering strategies, but
also the interrelated demographic, health and social
systems contexts.
SCHISTOSOMIASIS IN AFRICA
The mid-2003 estimates
A systematic review and collation of population
statistics for mid-2003 revealed the following esti-
mates: on a global scale, 779 million people were at
risk of schistosomiasis and 207 million individuals
were infected with schistosome worms (Steinmann
et al. 2006). Regarding the at-risk population, an
estimated 660 million were concentrated in Africa,
accounting for 85% of the global at-risk estimate.
An alarming 201.5 million schistosome infections
(mainly Schistosoma haematobium) were estimated to
occur in Africa, accounting for more than 97% of the
estimated number of infections worldwide.
Table 1 summarises the total population in Africa
in 2006 (WHO, 2008) and schistosomiasis preva-
lence estimates in mid-2003, stratiﬁed by country
(Steinmann et al. 2006). Care is indicated regarding
the country prevalence estimates, due to the scarcity
of up-to-date empirical data across large parts of
Africa (Brooker et al. 2009a, b). Guidelines issued
by WHO suggest a threshold of 10% of Schistosoma
spp., as determined by parasitological methods
in school surveys, to distinguish between low-
prevalence and moderate-prevalence communities.
At a threshold of 50%, distinction is made between
moderate-prevalence and high-prevalence commu-
nities (WHO, 2002). Adhering to these endemicity
cut-oﬀs, Fig. 1A depicts the schistosomiasis situation
across Africa in mid-2003, just before the launch
of a new wave of major schistosomiasis control
initiatives. Four countries in West Africa (i.e.
Burkina Faso, Ghana, Mali and Sierra Leone) and
three countries in East Africa (i.e. Madagascar,
Mozambique and the United Republic of Tanzania)
were classiﬁed as high-prevalence settings. Most
countries (n=29) were in the moderate-endemic
class with Schistosoma prevalence estimates ranging
between 10% and 50%. Schistosomiasis is absent
from Cape Verde owing to the absence of permissive
snail intermediate hosts, as well as Comoros and
Seychelles. The disease was eliminated fromTunisia
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some 30 years ago and is close to elimination in
Morocco (Laamrani et al. 2000; Engels et al. 2002).
Schistosomiasis occurs at prevalence levels below
10% in the remaining 12 countries and territories of
Africa.
Projected treatment needs with praziquantel
With the exceptions of Egypt (El-Khoby et al. 2000;
Fenwick et al. 2003) and Morocco (Laamrani et al.
2000; Engels et al. 2002), little progress was made in
the control of schistosomiasis on the African conti-
nent in the 1990s. However, recognizing the ex-
periences and successes of schistosomiasis morbidity
control programmes in Brazil, China and Egypt,
which emphasised the large-scale administration of
antischistosomal drugs, a sea change occurred in the
new millennium. Indeed, in May 2001, during the
54th World Health Assembly (WHA), a resolution
was passed and signed by over 200 member states.
Among other issues, the resolution urged member
states to attain, by 2010, a minimum target of regu-
larly administering anthelminthic drugs to at least
75% and up to 100% of all school-aged children at
risk of morbidity. In October 2001, WHO convened
an expert committee, during which the global strat-
egy for the prevention and control of schistosomiasis
and soil-transmitted helminthiasis was reﬁned
(WHO, 2002). The signiﬁcance of WHA Resolution
54.19 for the control of schistosomiasis has been
stressed elsewhere, including a concern that it might
thwart basic and operational research eﬀorts per-
taining to schistosomiasis (Colley, LoVerde and
Savioli, 2001; Colley and Secor, 2004). The key
points of WHA Resolution 54.19 and the reﬁned
global strategy for the prevention and control of
schistosomiasis and soil-transmitted helminthiasis
issuing from this WHA resolution and the WHO
expert committee meeting are discussed in an ac-
companying WHO editorial, published in this spe-
cial issue of Parasitology (Savioli et al. 2009).
An unfortunate aspect of a nearly unique focus on
large-scale anthelminthic drug administration was –
and continues to be – the lack of concern within the
global health community for prevention strategies
such as emphasising access to clean water, improved
sanitation and hygiene activities that could serve as
the backbone of multi-component integrated and
sustainable disease control programmes (Utzinger
et al. 2003). There is a fundamental disconnect be-
tween the substantial number of engineering projects
and community-led initiatives in the developing
world focusing on clean water and sanitation and the
vertical campaign-based nearly ‘drugs-only’ pro-
grammes (Singer and Castro, 2007). Hence, it is
important to recognize that eﬀorts to improve inter-
national health through better access to clean water
and sanitation will require intersectoral approaches
(Pru¨ss-U¨stu¨n et al. 2008; Bliss, 2009). This will
require advocacy and action from the health com-
munity to foster cooperative ventures with engin-
eering groups (e.g. non-governmental organizations
(NGOs), private foundations, government engin-
eering corps), and vice versa, to achieve sustainable
schistosomiasis control. Schistosomiasis is unique
in the context of ‘safe water and engineering’ as it
is the only signiﬁcant water-based disease that is
transmitted by direct water contact through skin
penetration rather than the faecal-oral route as most
other water-borne diseases. Costs upfront for im-
plementation of water supply and sanitation services
are high, which calls for the establishment of a
multilateral institution through which international
funds could be channelled, analogous to the Global
Fund to Fight AIDS, Tuberculosis, and Malaria
(Bliss, 2009). In addition, school-based control needs
to be mainstreamed into the school health plans of
education sectors (Bundy et al. 2006).
With praziquantel-based morbidity control –
ﬁrmly set as the centre pillar of the global strategy to
combat schistosomiasis – it is interesting to examine
strategic guidelines for recommended praziquantel
treatment schedules put forth by WHO (WHO,
2002). For high-prevalence communities, it is re-
commended to treat school-aged children once every
year; for moderate-prevalence communities, school-
aged children should be treated once every second
year; and for low-prevalence communities, the re-
commendation is to treat school-aged children twice
during primary schooling, i.e. best upon entry and
again before children are leaving school. Using these
strategic guidelines by considering country-speciﬁc
schistosome prevalence data summarised in Table 1
and assuming the basis of school-aged population
statistics from a recent WHO publication (WHO,
2008) that, on average, primary schooling in a typical
African setting lasts for six years, facilitated esti-
mation of praziquantel treatment needs. Table 1
summarises how many school-aged children would
require treatment with praziquantel at the unit of a
year, assuming that the goal of attaining a 100% target
be met. Fig. 1B depicts the projected annual number
of praziquantel treatments, stratiﬁed by country.
Recognizing that our estimates are based on a
number of assumptions, we calculate that approxi-
mately 128 million school-aged children would need
to be given praziquantel on a yearly basis. On
average, a school-aged child would be administered
between one and a half and three 600 mg tablets of
praziquantel (at the current recommended dosage of
40 mg/kg body weight), and hence between 192 and
384 million tablets would be needed in Africa alone
every year. This raises the question of whether this
amount of praziquantel tablets could be produced at
all. Based on an analysis for the year 2005, the answer
is yes, as ﬁve pharmaceutical companies (E.Merck in
Germany, Shin Poong in Korea and three companies
in China) produced a total of 200 metric tons of
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Table 1. Schistosomiasis endemicity across Africa at the onset of new control initiatives in mid-2003,
including stratiﬁcation of countries into three diﬀerent treatment strategies according to WHO
recommendations, and estimated numbers of school-aged children requiring praziquantel treatment at the
unit of a year (n.k., not known)
Country
Total
population
(in 2006)a
Estimated
country
prevalence of
schistosomiasis
(in mid-2003)b %
School-aged
children
(in 2006)a
Recommended
treatment
strategy for
school-aged
childrenc
Annualized
treatment needs
(number of
school-aged
children requiring
praziquantel)d
Algeria 33 351 136 7.7 6 439 550 C 2 146 517
Angola 16 557 050 44.4 4 579 784 B 2 289 892
Benin 8 759 653 35.5 2 362 443 B 1 181 222
Botswana 1 858 162 10.0 435 606 B 217 803
Burkina Faso 14 358 500 60.0 3 998 202 A 3 998 202
Burundi 8 173 070 13.3 2 194 133 B 1 097 067
Cameroon 18 174 696 12.0 4 686 315 B 2 343 158
Cape Verde 518 566 0 129 505 — 0
Central African
Republic
4 264 804 10.0 1 143 981 B 571 991
Chad 10 468 177 22.5 2 895 129 B 1 447 565
Comoros 818 434 0 213 131 — 0
Congo 3 689 299 34.2 957 947 B 478 974
Coˆte d’Ivoire 18 914 476 40.0 4 979 974 B 2 489 987
Democratic
Republic
of the Congo
60 643 888 28.2 16 814 811 B 8 407 406
Djibouti 818 509 <10 202 799 C 67 600
Egypt 74 166 499 10.0 15 831 851 B 7 915 926
Equatorial Guinea 495 640 2.0 129 017 C 43 006
Eritrea 4 692 115 7.2 1 205 528 C 401 843
Ethiopia 81 020 610 7.1 22 335 338 C 7 445 113
Gabon 1 310 818 45.5 305 518 B 152 759
Gambia 1 663 032 30.0 421 313 B 210 657
Ghana 23 008 442 72.5 5 686 077 A 5 686 077
Guinea 9 181 338 25.8 2 427 484 B 1 213 742
Guinea-Bissau 1 645 528 30.0 460 364 B 230 182
Kenya 36 553 490 23.0 9 421 761 B 4 710 881
Lesotho 1 994 888 <10 528 482 C 176 161
Liberia 3 578 922 24.0 992 411 B 496 206
Libyan Arab
Jamahiriya
6 038 644 5.0 1 150 276 C 383 425
Madagascar 19 159 010 55.0 5 203 413 A 5 203 413
Malawi 13 570 714 7.7 3 958 032 C 1 319 344
Mali 11 968 377 60.0 3 453 350 A 3 453 350
Mauritania 3 043 638 27.4 763 720 B 381 860
Mauritius 1 251 528 0.9 206 299 C 68 766
Morocco 30 852 969 0.01 6 195 422 — 0
Mozambique 20 971 446 69.8 5 622 469 A 5 622 469
Namibia 2 046 553 0.6 536 242 C 178 747
Niger 13 736 722 26.7 3 877 789 B 1 938 895
Nigeria 144 719 951 23.2 39 313 400 B 19 656 700
Rwanda 9 464 240 5.9 2 460 592 C 820 197
Sa˜o Tome´ and
Principe
155 125 3.8 40 967 C 13 656
Senegal 12 072 475 15.3 3 148 283 B 1 574 142
Seychelles 86 122 0 14 191 — 0
Sierra Leone 5 742 694 59.5 1 460 964 A 1 460 964
Somalia 8 445 395 18.0 2 223 289 B 1 111 645
South Africa 48 282 459 10.8 10 169 201 B 5 084 601
Sudan 37 707 483 14.9 9 725 540 B 4 862 770
Swaziland 1 133 613 25.6 297 248 B 148 624
Togo 6 410 428 26.7 1 713 121 B 856 561
Tunisia 9 878 000e 0 n.k. — 0
Uganda 29 898 598 20.4 8 885 525 B 4 442 763
United Republic
of Tanzania
39 458 708 51.5 10 554 923 A 10 554 923
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praziquantel active ingredient, which is equivalent
to 320 million tablets (Frost et al. 2008). However,
there are formidable challenges built around pro-
curement issues, shipment to the respective coun-
tries and distributions within-county to the most
remote areas and consumption of the drugs before
they expire and, despite the fact that praziquantel
has become cheap (less than US$ 0.10 per tablet),
the costs for treating 128 million children every
year cannot be neglected. In Nigeria, for example,
praziquantel would need to be administered to
almost 20 million school-aged children every year.
Table 1. (Cont.)
Country
Total
population
(in 2006)a
Estimated
country
prevalence of
schistosomiasis
(in mid-2003)b %
School-aged
children
(in 2006)a
Recommended
treatment
strategy for
school-aged
childrenc
Annualized
treatment needs
(number of
school-aged
children requiring
praziquantel)d
Western Sahara 440 000e 0 n.k. — 0
Zambia 11 696 161 26.6 3 325 628 B 1 662 814
Zimbabwe 13 228 195 40.0 3 456 759 B 1 728 380
TOTAL 942 138 990 127 948 946
a Total population estimates and the number of school-aged children (5–14 years) in 2006 were obtained from the 4 July
2008 Weekly Epidemiological Record (WHO, 2008).
b Country-speciﬁc estimates for schistosomiasis prevalence in mid-2003 were obtained from webappendix 2, put forth by
Steinmann and colleagues (2006).
c Countries were stratiﬁed into (A) high-prevalence (o50% of individuals infected) warranting treatment of school-aged
children once a year; (B) moderate-prevalence (10.0–49.9% of individuals infected) warranting treatment of school-
aged children once every two years; and (C) low-prevalence (<10% of individuals infected) warranting treatment of
school-aged children twice during schooling, once on school entry and once before leaving school (WHO, 2002).
d Annualized praziquantel treatment needs were estimated as follows: (A) for high-prevalence countries it is recommended
that school-aged children are treated once every year, hence we considered that the entire school-aged population is eligible
for treatment each year; (B) for moderate-prevalence countries it is recommended that school-aged children are treated
once every second year, hence we considered that half of the school-aged children are eligible for treatment every year;
(C) for low-prevalence countries it is recommended that school-aged children are treated twice during schooling (assuming
an average duration of 6 years), hence we considered a third of the school-aged population eligible for treatment each year.
e Population estimates for 2005 (source: World Population Prospects: The 2008 Revisions).
Fig. 1. Country-speciﬁc prevalence estimates for schistosomiasis in Africa, stratiﬁed into low-prevalence (<10%),
moderate-prevalence (10.0–49.9%) and high-prevalence (o50%) in mid-2003 (A) (source: Steinmann et al. (2006),
webappendix 2), and estimated annual treatment needs with praziquantel to be administered to school-aged
children (B).
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More than 5 million school-aged children would
require praziquantel treatment annually in another
eight countries, namely the Democratic Republic
of the Congo, Egypt, Ethiopia, Ghana, Madagascar,
Mozambique, South Africa and the United Republic
of Tanzania. The majority of African countries
and territories would require between 500 000 and
5 million school-aged children to be treated with
praziquantel every year. A further challenge in
certain countries is low school enrolment rates, es-
pecially in West Africa where enrolment can be as
low as 30% (WHO, 2008). Hence, innovative ap-
proaches are required to target non-enrolled children
to enhance compliance. Finally, a number of mainly
sparsely-populated countries and territories, classi-
ﬁed as low-prevalence settings where school-aged
children would need to be treated twice during
primary schooling, might be targeted for schisto-
somiasis elimination (e.g. Djibouti, Equatorial
Guinea, Eritrea, Lesotho, Libyan Arab Jamahiriya,
Mauritius, Namibia and Saˆo Tome´ and Principe).
The following issues are important when inter-
preting our projected annual treatment needs with
praziquantel. First and foremost, these estimated
treatment needs are based on a number of assump-
tions, which need scrutiny. Indeed, there is a paucity
of reliable, up-to-date and spatially-explicit empiri-
cal data regarding schistosome infection distri-
butions, especially at the local level (Brooker et al.
2009a, b). In the absence of such data, we utilised
country-speciﬁc schistosome prevalence estimates
for mid-2003 (Steinmann et al. 2006). However, a
key epidemiological feature of schistosomiasis is its
focal distribution (Lengeler et al. 2002; Brooker et al.
2009a), and hence such broad-scale prevalence esti-
mates belie themarked variation in prevalence within
countries, and even within moderate- and low-
prevalence countries there may remain large pockets
of high prevalence. This aspect further emphasises
the importance of having detailed information on the
geographical distribution of schistosomiasis at local
levels and in real time in order to target treatment to
areas in greatest need. The scope and limits of rapid
mapping surveys, including rapid diagnostic tests,
warrant further exploration (Brooker et al. 2009a ;
Stothard, 2009). Keeping sustainable control in
mind, the same approaches in mapping, surveillance
and predictions can be used to target combined
biomedical, health education and engineering inter-
ventions in the same communities.
Secondly, it is interesting to note that, in mid-
2003, the number of schistosome infections in Africa
was estimated at 201.5 million (Steinmann et al.
2006). In view of our current estimate of 128 million
school-aged children warranting praziquantel treat-
ment per year, some 72.5 million infections would be
missed. Focusing treatment and control activities of
schistosomiasis exclusively on school-aged children
might therefore need reinvestigation. In highly
endemic areas, for example, preschool-aged children
(Stothard and Gabrielli, 2007) and other high-
risk groups such as ﬁshermen, car washers and
sand harvesters (Melman et al. 2009) must be
considered.
Thirdly, the Schistosomiasis Control Initiative
(SCI), which is discussed in greater detail below,
assisted six African countries in establishing and
implementing their national schistosomiasis control
programmes. Annual treatment needs with prazi-
quantel in these SCI-supported countries (i.e.
Burkina Faso,Mali, Niger, Uganda, United Republic
of Tanzania and Zambia), according to our estimates,
would amount to 26 million school-aged children.
The actual number of individuals treated every year
between 2005 and 2008, according to SCI data
published in this special issue of Parasitology
(Fenwick et al. 2009) ranged between 8.2 and 12.8
million. One might therefore conclude that coverage
ranged between 31% and 49%. However, one of
the ﬁrst steps of scaling-up schistosomiasis control
activities within SCI-supported countries was to
delineate high-risk areas. Hence, the control pro-
grammes took into consideration, as best they could,
the focal distribution of schistosomiasis in an eﬀort to
enhance the cost-eﬀectiveness of treatment inter-
ventions (Clements et al. 2006, 2008; Brooker et al.
2008). It follows therefore that projected prazi-
quantel treatment needs presented in Table 1 and
displayed in Fig. 1B, might considerably overesti-
mate the real annual needs. This is an important issue
when estimating coverage, and hence it is conceiv-
able that SCI-supported countries reached coverage
rates among the school-aged population that were
close to the 75–100% targets issued in WHA
Resolution 54.19. Little is known, however, about
treatment needs, coverage rates and adherence over
time during active control programmes. For ex-
ample, will praziquantel administration – year after
year – really be necessary in high-prevalence com-
munities or is there scope for ‘treatment holidays’?
Will children who feel better after the ﬁrst or second
treatment round be willing to take praziquantel again
and again? Experience from China suggests that
adherence to praziquantel treatment declines during
prolonged large-scale chemotherapy-based control
eﬀorts (Guo et al. 2005). How could a rapid and in-
expensive yet accurate monitoring and surveillance
component be integrated into a schistosomiasis
control programme, resulting in real-time prevalence
estimates, which in turn will guide the frequency of
treatment longitudinally? Simple questionnaires
administered through the education system have
proven useful for rapid and inexpensive identiﬁ-
cation of high-risk communities of urinary schisto-
somiasis, but we do not know how they perform over
time during active control (Lengeler et al. 2002).
Recent research from Zanzibar suggests that reagent
strips for measuring blood in urine as a proxy
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for S. haematobium infection among school-aged
children perform well over the course of a schisto-
somiasis control programme (French et al. 2007).
There is a need for developing and validating novel
rapid diagnostic and mapping tools (Brooker et al.
2009a ; Stothard, 2009).
Another issue needs highlighting: the spatial dis-
tribution of schistosomiasis in Mali showed little
change when comparing data from the mid-1980s
before instigating a national control programme,
with data from 2004, when SCI support facilitated
the re-establishment of a national schistosomiasis
control programme. This experience demonstrates
that an externally-funded control programme
(German Technical Cooperation; GTZ), which
emphasised large-scale administration of prazi-
quantel, failed to become sustainable, as the situation
reverted to pre-interventions levels after several
years of no drug interventions (Clements et al. 2009).
Two features that are diﬀerent when comparing the
1980s, when the schistosomiasis control programme
in Mali was funded through GTZ, and the current
SCI activities are the larger scale of operation and
the signiﬁcantly lower cost of praziquantel in the
new era. However, the SCI-supported activities are
unlikely to be sustainable. They continue to impose a
strong dependence on drugs for de-worming already
infected persons while addressing insuﬃciently the
need for prevention of re-worming. Intersectoral
co-operation, particularly the co-ordination with
engineering groups and encouraging community-led
activities, could target clean water and sanitation
provision. In addition, collaboration with the edu-
cation sector is crucial forhealth education,ultimately
leading to behavioural changes towards improved
hygiene activities. These steps, carried out in the
same communities where praziquantel is adminis-
tered annually could lead to sustainable reduction, if
not elimination, of schistosomiasis. The prevention
component of such a programme would provide for
a substantially reduced demand for praziquantel.
Moreover, an impact beyond the target disease
schistosomiasis is likely to occur as recently demon-
strated in China where an integrated schistosomiasis
control approach showed an ancillary eﬀect on soil-
transmitted helminthiasis (Wang et al. 2009a).
It is worth noting that the highest number of
individuals treated with praziquantel during the SCI
campaigns – 12.8 million in 2005 – accounted for
10% of the estimated treatment needs among school-
aged children on the African continent. It would
be interesting to know how many praziquantel
treatment courses were administered concurrently
through other vertical control programmes (e.g.
Carter Foundation operating in Nigeria and else-
where (Richards et al. 2006), local NGOs and re-
search institutions (TchuemTchuente´ andN’Goran,
2009)), as well as more horizontally through the
existing health systems.
Finally, in view of the focal distribution of
schistosomiasis and the chronic nature of the disease
with mainly subtle morbid sequelae, the following
proposal has beenmade. Entire at-risk populations in
Africa should be targeted with praziquantel for at
least 5 years. An estimated 400 million people would
need to be treated, amounting to 1.2 billion prazi-
quantel tablets every year. The costs have been es-
timated at US$ 100 million per year (Hotez and
Fenwick, 2009). The challenge of implementing such
a large-scale vertical control approach cannot be
over-emphasised, including issues of coverage, ad-
herence and the risk for the development of prazi-
quantel resistance. The costs and beneﬁts of this
proposal should be carefully examined and compared
to other more integrated and sustainable control
approaches emphasising health education, water,
sanitation and hygiene activities.
NEGLECTED TROPICAL DISEASES
Collective burden
Schistosomiasis is but one of several so-called ne-
glected tropical diseases that are pervasive in Africa
and elsewhere in the developing world. An initial
inventory listed 13 neglected tropical diseases: seven
helminth infections (i.e. schistosomiasis, along with
three common soil-transmitted helminth infections
(ascariasis, hookworm disease and trichuriasis),
dracunculiasis, lymphatic ﬁlariasis and onchocer-
ciasis), three vector-borne protozoan infections
(Chagas disease, humanAfrican trypanosomiasis and
leishmaniasis) and three bacterial infections (Buruli
ulcer, leprosy and trachoma) (Hotez et al. 2006).
Moreover, cysticercosis/taeniasis and food-borne
trematodiasis were explicitly stated as neglected
tropical diseases in the Hotez et al. (2006) landmark
review. Meanwhile, the case has been made for in-
clusion of a host of additional neglected tropical
diseases. The WHO, for example, in a 2006 publi-
cation listed cholera/epidemic diarrhoeal disease,
dengue/dengue haemorrhagic fever and endemic
treponematoses (e.g. yaws, pinta and endemic
syphilis) alongside the above-mentioned 13 diseases
(WHO, 2006a). One year later, the Public Library of
Sciences (PLoS) launched a new journal – PLoS
Neglected Tropical Diseases – which is exclusively
devoted to research and control of the neglected
tropical diseases (Hotez, 2007). The scope of PLoS
Neglected Tropical Diseases has evolved since its
inaugural issue in October 2007 and now includes
additional helminth, bacterial and protozoan infec-
tions, as well as tropical fungal and viral infections
(Hotez and Yamey, 2009).
Focusing on the initial 13 neglected tropical dis-
eases put forth by Hotez and colleagues (2006), it
is interesting to examine global burden estimates.
Fig. 2A shows disease-speciﬁc burden estimates for
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the year 2002, drawing on diﬀerent data sources. Of
note, for schistosomiasis, the global burden has been
estimated at 1.7 million DALYs according to annexe
table 3 of the World Health Report 2004 (WHO,
2004), whereas a WHO expert committee put forth
an estimate of 4.5 million DALYs (WHO, 2002).
The most dramatic uncertainty occurs around
hookworm disease, with estimates ranging between
59000 DALYs to 22.1 million DALYs, a 375-fold
diﬀerence (WHO, 2002; Hotez et al. 2006). It is
also noteworthy that, at present, no estimates are
available for Buruli ulcer and the myriad of other
neglected tropical diseases. Taken together, the
global burden of the 13 neglected tropical diseases
featured in Fig. 2A, ranges between 17.7 million
DALYs (WHO, 2004) and 56.6 million DALYs
(Hotez et al. 2006). There is a clear need to reconcile
such diﬀering estimates based on a coherent scientiﬁc
inquiry.
Fig. 2B compares the global burden estimate for
the initial set of 13 neglected tropical diseases with
the other major communicable diseases (Lopez et al.
2006). There is a growing consensus that the ‘true’
collective burden of the neglected tropical diseases is
considerably higher than currently appreciated; this
can be explained in at least two ways. Firstly, there
are high incidence rates for many of the neglected
tropical diseases but their disability weights are
seriously underestimated (Jia et al. 2007; Finkelstein
et al. 2008). Secondly, at present, virtually no burden
estimates are available for several of the neglected
tropical diseases (e.g. Buruli ulcer, cysticercosis/
taeniasis, food-borne trematodiasis and strongyloi-
diasis). New research pertaining to schistosomiasis,
including decision tree modelling, a validated quality
of life approach, systematic reviews and meta-
analyses suggest that the true burden might be
several-fold higher than the upper WHO estimate of
4.5 million DALYs (King et al. 2005; King and
Dangerﬁeld-Cha, 2008). We applaud new eﬀorts to
re-estimate the global burden and risk factors of
more than 150 diseases. Schistosomiasis and the
neglected tropical diseases at large are part of the
communicable disease cluster with dozens of experts
pursuing systematic reviews of the published and
unpublished literature and extracting data in a
standardized manner which will ultimately lead to
more accurate and consistent global burden esti-
mates (Murray et al. 2007; King and Bertino, 2008).
In recent years, there has been growing advocacy,
political will and international interest in scaling up
the control of neglected tropical diseases, going
hand-in-hand with a changing funding landscape
with new opportunities for research and develop-
ment of the next generation of drugs, diagnostics and
vaccines (Moran, 2005; Keiser and Utzinger, 2007;
Kolaczinski et al. 2007; Hotez et al. 2009). The re-
cent publications of the genomes of S. mansoni and
S. japonicum will add further impetus for target-
based drug, diagnostics and vaccine discovery
Fig. 2. Global burden estimates of the initial set of 13 neglected tropical diseases, including current uncertainties
(A) (source: WHO, 2004; Hotez et al. 2006) and comparison of global burden estimates of the neglected tropical
diseases with other major communicable diseases (B) (source: Lopez et al. 2006).
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(Berriman et al. 2009; The Schistosoma japonicum
Genome Sequencing and Functional Analysis Con-
sortium, 2009). However, health sector advocacy
regrettably continues to ignore the pressing need for,
and long-term beneﬁts of, integration with the en-
gineering sector and vice versa (Singer and Castro,
2007).
Contemporary control initiatives
In view of the growing awareness of the high col-
lective burden due to the neglected tropical diseases
and the mounting advocacy that controlling these
diseases is a key factor to ascertain progress towards
achieving the millennium development goals (Hotez
et al. 2007b), it is not surprising that new alliances
have been formed and signiﬁcant new ﬁnancial,
operational and technical resources have become
available. Two of the most powerful arguments that
convinced the donor community, public health ex-
perts and disease control managers alike to invest
in the simultaneous control of multiple neglected
tropical diseases were: (1) the issue of co-endemicity
(i.e. multiple neglected tropical diseases occur in
the same individual (polyparasitism) and they are
entrenched in the same communities) (Raso et al.
2004; Brady, Hooper and Ottesen, 2006; Brooker
and Clements, 2009), and (2) access to a readily
available and simple public health intervention,
namely the deployment of safe and eﬃcacious drugs
at a large scale for morbidity control (Molyneux,
Hotez and Fenwick, 2005; Hotez et al. 2006, 2007b).
The changing landscape of the neglected tropical
diseases and its control is also mirrored in the peer-
reviewed literature from 2005 onwards. Prominent
language associated with the control of the neglected
tropical diseases include, among other statements:
‘rapid impact packages’, ‘pro-poor strategies ’,
‘quick ﬁxes’ and ‘best buy in public health’. Such
articulations generally go hand-in-hand with vertical
control programmes, emphasising a mass campaign
approach. Justiﬁcation for such a mass campaign is
encapsulated in the following statement ‘need for
parallel delivery systems because of health system
failures ’. Box 1 summarises advantages and disad-
vantages of mass campaigns versus a more horizontal
health systems approach. Throughout, however,
there is a pervasive blind spot in the health com-
munity that avoids coming face-to-face with the
fact that integrated engineering-biomedical solutions
supported by local communities are required for
long-term success (Utzinger et al. 2003; Singer and
Castro, 2007).
Issuing fromWHA Resolution 54.19 was a call for
action and, thanks to a US$ 30million grant from the
Bill and Melinda Gates Foundation, the London-
based SCI got oﬀ the ground in 2003 (Fenwick et al.
2009; Savioli et al. 2009). In line with the WHA
resolution and strategic guidelines put forth by
WHO, SCI aimed from its onset at the concurrent
control of schistosomiasis and soil-transmitted hel-
minthiasis (Fenwick et al. 2009). The central feature
of control was the large-scale administration of an-
thelminthic drugs to at-risk populations (i.e. school-
aged children) without prior diagnosis, a strategy
now termed ‘preventive chemotherapy’ (WHO,
2006b). Deployment of anthelminthics (praziquantel
against schistosomiasis and albendazole or meben-
dazole against common soil-transmitted helminth
infections) was primarily executed through the
education system once or twice a year. Table 2
emphasises that ‘preventive chemotherapy’, regular
anthelminthic drug administration and universal
access to eﬀective, low-cost treatments have been
endorsed in the mission statements of the Preven-
tive Chemotherapy and Transmission Control
Box 1. Advantages and disadvantages of mass campaigns and systemic control approaches.
Mass campaign approach
Advantages Disadvantages
$ Easy to argue $ Supply driven
$ Promise of immediacy $ Lacks sustainability
$ Promise of easy accountability $ Limited in time and place
$ Promise of time-limited investment $ Requires external logistics
$ Suitable for eradicable problems $ Can fragment/undermine routine services
$ Can integrate across campaigns $ Diﬃcult to align and harmonize with local/
decentralized health planning$ High temporary impact
$ Quick equitable coverage $ Oﬀ national health budgets
$ Create temporal inequities
Systemic approach
Advantages Disadvantages
$ Demand-driven $ Diﬃculties of accountability
$ Public good and universal right $ Considered too costly
$ Can integrate across services $ Considered as too slow to respond
$ Broad applicability, as suitable for all kinds of
health interventions
$ Sustainability
$ Approach normative circumstances
$ High cumulative impact
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Department of WHO, SCI and the Global Net-
work for Neglected Tropical Diseases. Approaches
of preventive environmental management and
community-led total sanitation are largely missing
from this discussion.
INTEGRATED CONTROL
What is meant by integration?
There is a growing body of literature on the
integrated control of neglected tropical diseases
(Lammie, Fenwick and Utzinger, 2006; Hotez et al.
2007a ; Kolaczinski et al. 2007; Gre´pin and Reich,
2008; Rumunu et al. 2009). However, it is the
understanding of the term ‘integration’ that matters.
According to the Oxford English Dictionary, in-
tegrated is deﬁned as follows: ‘Combined into a
whole ; united; undivided’, and ‘Uniting in one
system several constituents previously regarded as
separate’. Drawing on this deﬁnition, it is correct,
albeit very narrow that uniting two or more drugs
(previously used in separate applications, targeting
diﬀerent diseases), for the simultaneous control of
multiple neglected tropical diseases can be con-
sidered integrated. However, deploying two rather
than a single anthelminthic drug utilises one and the
same tool; a drug to control morbidity. Can such a
‘magic bullet ’ approach work, and is it sustainable?
Clearly, there are other and much more compre-
hensive ways of uniting multiple constituents to
achieve a truly integrated approach. The most ob-
vious one is the strengthening of the health system,
which then serves as the backbone for drug delivery
and myriad other preventive and curative services.
Other ways of integration entail the administration of
anthelminthic drugs through the existing education
system, alongside with locally-adapted health edu-
cation messages and, if need be, nutrition pro-
grammes (Bundy et al. 2006; Stothard et al. 2006).
Improving access to clean water and adequate
sanitation necessitates bridge building between the
health and engineering sectors (Singer and Castro,
2007; Bliss, 2009). Whenever possible, such inter-
programmatic and intersectoral collaborations should
be fostered to increase the chances of sustainable
control of multiple neglected tropical diseases
(Utzinger et al. 2005; Holveck et al. 2007). Most
importantly, if we wish to achieve sustainability of
any disease control eﬀorts beyond cycles of funding,
integrated neglected tropical disease control implies
full integration into the existing health and social
systems; not only into the public systems but into the
system and network of all existing health services
providers in a given area. This requires systemic
approaches that are readily aligned and harmonised
with locally-owned national programmes (Utzinger
and de Savigny, 2006).
Prospect and challenges
With growing emphasis on, and need for, integrated
control of neglected tropical diseases, new insight has
been gained regarding the prospect and challenges
of this approach (Kolaczinski et al. 2007; Rumunu
Table 2. Organizations and initiatives and their mission statements regarding the prevention and control
of schistosomiasis and other neglected tropical diseases (emphasis added in bold)
Organizations and
initiatives Mission statement Reference – Website
World Health
Organization
(WHO), Preventive
Chemotherapy and
Transmission
Control
‘To provide national programmes with technical guidelines
that emphasize a coordinated, cost-eﬀective approach to the
implementation of national elimination and control activities
where preventive chemotherapy is the main tool, i.e. regular
anthelminthic drug administration to all people at risk of
morbidity due to helminthic diseases, starting early in life’.
http://www.who.int/
neglected_diseases/
preventive_
chemotherapy/en/
Schistosomiasis
Control Initiative
(SCI)
‘To help those who suﬀer from and are at risk of neglected tropical
diseases (NTDs) in sub-Saharan Africa. We aim to achieve this by:
(i) creating awareness, changing perceptions and fostering global
support for national NTD programmes; (ii) promoting eﬀective
collaboration and developing key partnerships in order to mobilize
resources against NTDs; (iii) empowering governments to run
successful and sustainable national NTD control programmes;
(iv) ensuring universal access to eﬀective treatment to
everyone who suﬀers from NTDs; (v) building the capacity of civil
society and aﬀected communities to break the cycle of transmission;
and (vi) developing and deploying a new generation of improved
preventative and therapeutic tools and strategies to eliminate NTD’.
http://www.sci-ntds.org/
Global Network for
Neglected Tropical
Diseases
‘To end global suﬀering and death from neglected tropical diseases
(NTDs) through eﬀective, low-cost treatments ’.
http://globalnetwork.org/
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et al. 2009). Several issues are elaborated here. The
ﬁrst one pertains to co-endemicity, and hence co-
morbidity, which is of considerable public health
relevance and oﬀers opportunities for integrated
control. It has been speculated that the control of
seven neglected tropical diseases can be attained
in a cost-eﬀective manner through administration
of just four drugs (Molyneux et al. 2005). Control
interventions could be further enhanced through
targeting of co-endemic areas, and the important
role of geospatial tools (geographical information
systems, remote sensing and spatial statistics) must
be emphasised (Brooker and Utzinger, 2007). To
illustrate this issue, the following example is pro-
vided. In a cross-sectional epidemiological survey
carried out in 57 schools of western Coˆte d’Ivoire,
some 4000 children were examined for S. mansoni,
soil-transmitted helminths andmalaria parasitaemia.
Focusing on S. mansoni and hookworm, it was found
that 19% of the children were co-infected, whereas
24% were infected with either S. mansoni or hook-
worm (Raso et al. 2005, 2006a, b). Risk maps of
single infections, mono-infections and co-infection
were produced using Bayesian-based geostatistical
models that included demographic, environmental
and socio-economic covariates (Raso et al. 2005,
2006a, b, 2007;Vounatsou et al. 2009). The riskmaps
produced for S. mansoni and hookworm single
infections and for S. mansoni-hookworm co-
infections are shown in Fig. 3. Interestingly, the
prediction of mono-infections revealed distinctive
and quite diﬀerent spatial patterns compared to
single infection risk maps, particularly for hook-
worm. It is conceivable that the relative importance
ofmono-infections in settings where several parasites
co-exist will increase in the face of repeated large-
scale anthelminthic drug administration, as the
likelihood of co-infection with multiple parasites
decreases. This means that an increasing proportion
of individuals will be treated with two drugs
unnecessarily (Raso et al. 2007).
Secondly, co-administration of drugs targeting
multiple neglected tropical diseases requires detailed
safety and eﬃcacy investigations (Reddy et al. 2007),
and there is a need for establishing pharmacovigil-
ance platforms. Moreover, regular administration of
multiple drugs at a large scale poses the risk of de-
velopment and spread of drug-resistant parasites
(Smits, 2009). This issue already causes great econ-
omic losses in livestock production (James, Hudson
and Davey, 2009). Clearly, there is a need for estab-
lishing and standardizing protocols for anthelminthic
drug eﬃcacy monitoring (Scherrer et al. 2009) and
for early detection of multi-parasite drug resistance.
The third issue refers to tools and strategies that
are required for integrated and sustainable control
Fig. 3. Predicted risk maps for no infection (A), S. mansoni mono-infection (B), hookworm mono-infection (C),
and S. mansoni-hookworm co-infections (D) in the region of Man, western Coˆte d’Ivoire (sources: Raso et al., 2005,
2006a, b).
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of multiple neglected tropical diseases. There are
diverse needs for diﬀerent diseases. For the helmin-
thic diseases (e.g. schistosomiasis, soil-transmitted
helminthiasis, lymphatic ﬁlariasis and onchocer-
ciasis) and trachoma, the recommended strategy for
their control in highly endemic areas relies on the
large-scale and regular administration of anthel-
minthic drugs. Spatially-explicit risk proﬁling is an
important ingredient, due to the focal distribution of
helminth infections. At an early stage of control, an
integrated chemotherapy approach holds promise for
control of co-morbidity. To lower dependency on a
‘drugs-only’ approach and to enhance sustainability,
from the onset of control, complementary measures
should be implemented, which will depend on
available resources (Utzinger et al. 2003; Smits,
2009). The package of intervention needs to be
tailored to a given eco-epidemiological setting and
adjusted and ﬁne-tuned over time as the nature and
impact of control changes. With regard to bacterial
infections such as Buruli ulcer and leprosy, and
vector-borne protozoan infections, such as human
African trypanosomiasis and leishmaniasis, case
ﬁnding and management is of central importance.
The strengthening of health systems is the key
prerequisite to facilitate integrated and sustainable
control of neglected tropical diseases.
Finally, the diﬀering starting points and end-
points of control of diﬀerent neglected tropical dis-
eases must also be considered, including recognition
of diagnostic challenges at diﬀerent stages of control
(Bergquist, Johansen and Utzinger, 2009; Stothard,
2009). A system of real-time and ﬂexible monitoring
should allow adaptation of strategies and targets
as control programmes move along. Experience
and lessons learnt from implementing a national
schistosomiasis control programme in China for over
half a century are instructive and might stimulate
control coordinators in Africa (Wang, Utzinger and
Zhou, 2008).
The way forward
In our view, strong district health systems that
are nationally-owned are the main prerequisite for
successful, cost-eﬀective and sustainable control
of neglected tropical diseases. For achieving a true
integration of disease control, interventions must
be readily adapted to the local endemic settings,
based upon local priorities and idiosyncrasies, using
locally-owned resources and targeting those at
greatest need. Hence, besides the environment, the
prevailing demographic, health and social systems
contexts need to be considered (Wang et al. 2008;
Gurarie and Seto, 2009).
We feel that vertical mass campaigns and broad
systemic approaches are not mutually exclusive. In
contrast, the two approaches can be aligned and
combined and, if properly co-ordinated allow the
harnessing of complementarities and synergies.
Campaigns hold the greatest promise for health
issues that are characterized by a wide geographical
distribution, aﬀecting a large proportion of the
population and representing a dominant factor re-
garding economic and social development. Unfor-
tunately, over large parts of Africa, schistosomiasis
and other helminthic infections still meet these
characteristics, and hence disease-associated mor-
bidity is rampant. Large-scale anthelminthic drug
administration through vertical control programmes
is therefore still required for the foreseeable future.
Once morbidity control is consolidated, the strategy
must shift to transmission control emphasising
access to clean water and adequate sanitation, as
demonstrated in successful past helminth control
programmes in the southern United States (Stiles,
1939) and as currently witnessed in China (Wang
et al. 2009b). Adequately equipped and staﬀed
routine health systems that are readily embedded and
owned by the country will ultimately provide good,
comprehensive and permanent quality health care.
Alongside this vision, it is of paramount importance
to repair the broken bridges between the biomedical
and engineering sectors that would have the most
profound positive eﬀect on control of neglected
tropical diseases. The essential role of this linkage
was recognized and acted upon in the early decades of
the past century (Stiles, 1939). The past lies ahead of
us and re-forging co-operative linkages here is a top
priority for the future.
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